Dermatology
Partner With Us
Advertisement
Conexiant chevron_right Dermatology chevron_right Phase 3 Data Nemolizumab for Prurigo Nodularis Relief
From the Journals

Phase 3 Data: Nemolizumab for Prurigo Nodularis Relief

Conexiant
article Full Article subject Summary summarize Notecard
A recent study published in JAMA Dermatology demonstrated that nemolizumab, a monoclonal antibody targeting interleukin-31 signaling, significantly reduced pruritus and skin lesions in patients with moderate to severe prurigo nodularis. The phase 3 randomized clinical trial, OLYMPIA 1, showed that nemolizumab was associated with a 58.4% reduction in pruritus compared to 16.7% in the placebo group by week 16. The findings indicate the efficacy and safety of nemolizumab in treating prurigo nodularis.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.